Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is a heavily desmoplastic and immunologically quiescent tumor. This complex immunosuppressive tumor microenvironment (TME) and marked desmoplasia act to insulate the tumor against an effective cytotoxic immune response. Thus far, no single immunotherapy strategy has proved to be effective, warranting investigation of combination approaches to improve efficacy. The potential of fibroblast activation protein (FAP) targeted radionuclide therapy (TRT) using 177 Lu-FAP-2286 to induce immunogenic cell death and reshape the TME was assessed in vitro and in vivo. Then, 177 Lu-FAP-2286 and CAR-T therapy were sequentially used in PDAC model mice to evaluate their combinatory efficacy. 177 Lu-FAP-2286 could induce the immunogenic death of FAP + cancer-associated fibroblasts (CAFs) and nearby cancerous cells, shifting the PDAC microenvironment toward a more permissive, pro-inflammatory state, thereby greatly enhancing CAR-Ts tumor accumulation and in vivo persistence. The sequential use of low-dose TRT and a single dose of CAR-Ts achieved a parallel outcome as two infusions of CAR-Ts therapy. The sequential use of TRT and CAR-T therapy may partially alleviate the burden of CAR-T administration and represents a promising strategy worthy of further translational evaluation in immunotherapy‑refractory PDAC.
No takes yet. Share an insight, caveat, or question.
Niu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: